智通财经网·2025-06-05 12:03Group 1 - Lianhua Technology's K-amine product maintains stable gross profit and has not received any increase in customer demand notifications [1] - Yara International's supervisor Peng Zhiyun is under investigation for insider trading, which is unrelated to the company's operations [2] - Sangfor Technologies' application for a new drug, a recombinant human anti-IL-1β monoclonal antibody injection, has been accepted for review by the National Medical Products Administration [3] Group 2 - Maipu Medical plans to acquire 100% equity of Yijie Medical and raise matching funds, with the stock resuming trading [4] - ZaiJing Pharmaceutical signed an exclusive marketing service agreement for a recombinant human thyroid-stimulating hormone injection, with potential revenue of up to RMB 250 million [5] - Haitai Development is planning to purchase controlling interest in Zhixueyun, which may constitute a major asset restructuring [6] Group 3 - Shuyou Pharmaceutical's STSP-0601 injection has been included in the priority review list by the National Medical Products Administration [7] - Yuyin Co. confirmed no undisclosed major matters affecting stock trading amid abnormal price fluctuations [8][9] - Chengdi Xiangjiang's subsidiary won a bid for a RMB 440 million project with China Mobile for data center power system construction [10] Group 4 - Huamai Technology's business focuses on communication infrastructure, with no significant changes in the market environment [11] - Huijin Co. reported normal production and operations, confirming no undisclosed major matters amid stock price fluctuations [12] Group 5 - Wenta Technology's shareholder plans to reduce holdings by up to 3% [15] - Jingfang Technology's investor intends to reduce holdings by no more than 2% [15] - Yanmian Technology's controlling shareholder plans to reduce holdings by up to 2% [15] - Debang Technology's national integrated circuit fund has cumulatively reduced its holdings by 1% [15] - Lanjian Intelligent plans to repurchase shares worth between RMB 10 million and 20 million [15] - Chengdi Xiangjiang's joint venture won a RMB 440 million project [15] - Alter signed a RMB 214 million technology development contract [15] - Zhongyou Engineering's subsidiary received a contract worth approximately RMB 2.122 billion for a gas pipeline project in Iraq [15]